Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | HINT1 | P49773 | 5/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200375 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23200376 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL780400 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710671 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL800874 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710670 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7535718 | 0.92 | HINT1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7541561 | 0.89 | TAAR1 (0.56) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7111072 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL2424287 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2025-11-27 | — | — | US | claimed |
| EP-3368089-B1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA INC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12318489-B2 | Nanoparticle formulations for delivery of nucleic acid complexes | TRANSLATE BIO MA, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20250064986-A1 | OPTIMIZED POLYNUCLEOTIDES FOR PROTEIN EXPRESSION | PRECISION BIOSCIENCES, INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-12195750-B2 | Inducible CRISPR system expression and applications thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-01-14 | — | — | US | claimed |
| EP-4460334-A1 | OPTIMIZED POLYNUCLEOTIDES FOR PROTEIN EXPRESSION | Precision BioSciences, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| US-11998567-B2 | Engineered chimeric guide RNA and uses thereof | NANJING BIOHENG BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | claimed |
| US-11781141-B2 | Influenza-activated constructs and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-10-10 | — | — | US | claimed |
| WO-2023133525-A1 | OPTIMIZED POLYNUCLEOTIDES FOR PROTEIN EXPRESSION | PRECISION BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| EP-3765612-A1 | ENGINEERED CHIMERIC GUIDE RNA AND USES THEREOF | Nanjing Bioheng Biotech Co., Ltd (CN) | 2021-01-20 | — | — | EP | claimed |
| WO-2019173942-A1 | ENGINEERED CHIMERIC GUIDE RNA AND USES THEREOF | NANJING BIOHENG BIOTECH CO., LTD (CN) | 2019-09-19 | — | — | WO | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| US-20180055869-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | TRANSLATE BIO MA, INC. (US) | 2018-03-01 | — | — | US | claimed |
| EP-3256592-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | TRANSLATE BIO MA, INC. (US) | 2017-12-20 | — | — | EP | claimed |
| WO-2017075038-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | RANA THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| WO-2016130963-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2016-08-18 | — | — | WO | claimed |
| EP-3033424-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | Rana Therapeutics, Inc. (US) | 2016-06-22 | — | — | EP | claimed |
| US-20150050738-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | US | claimed |
| WO-2015023975-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | TAAR1 4201/4885HINT1 3379/4885NT5E 619/4885 |
| US-12318489-B2 | Nanoparticle formulations for delivery of nucleic acid complexes | DIS3, SYNCRIP, EXOSC5 | TAAR1 4201/4885HINT1 3379/4885NT5E 619/4885 |
| US-20250360089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | TAAR1 4201/4885HINT1 3379/4885NT5E 619/4885 |
| US-20180055869-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RNASE1, NSUN3, NSUN2 | TAAR1 4387/4885HINT1 2896/4885NT5E 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.